Asahi shares mark weekly slide after cyberattack halts production
CalciMedica, Inc. (NASDAQ:CALC), a small-cap biotech company valued at $42 million, saw Chief Medical (TASE:BLWV) Officer Sudarshan Hebbar report purchasing shares of the company’s common stock in two transactions, totaling $16,361. According to InvestingPro data, analysts have set ambitious price targets ranging from $14 to $20 for the stock.
On August 14, 2025, Hebbar acquired 1,584 shares at a weighted average price of $2.585, with prices ranging from $2.57 to $2.61, for a total value of $4,095. The following day, August 15, 2025, he purchased an additional 4,392 shares at a weighted average price of $2.793, with prices ranging from $2.70 to $2.85, for a total value of $12,266. While InvestingPro analysis shows the company is quickly burning through cash, it maintains a healthy current ratio of 5.45, indicating strong short-term liquidity.
Following these transactions, Hebbar directly owns 51,976 shares of CalciMedica. Track insider transactions and access 7 additional key insights about CALC with InvestingPro.
In other recent news, CalciMedica Inc. announced the design and rationale of its Phase 2 KOURAGE trial for Auxora, aimed at treating acute kidney injury (AKI) with respiratory failure. The publication, featured in the American Journal of Nephrology, includes preclinical data indicating that Auxora significantly increased the glomerular filtration rate in rat models of AKI. Additionally, a post-hoc analysis from CalciMedica’s CARDEA trial revealed a 62.7% relative reduction in mortality among COVID-19 patients with AKI treated with Auxora compared to a placebo. In another development, CalciMedica has appointed Baker Tilly US, LLP as its new accounting firm following a merger with Moss Adams LLP. The transition was approved by the Board of Directors’ Audit Committee and was effective immediately. The audit report from Moss Adams for the year ending December 31, 2024, was issued without adverse opinions or modifications. CalciMedica confirmed no disagreements with Moss Adams regarding accounting practices or financial disclosures during 2023 and 2024, or in the interim period before the merger.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.